基本信息
浏览量:21
职业迁徙
个人简介
I’m Hsiang-Wen Tseng, the Vice President of Preclinical Testing Center at Level Biotechnology Inc. I am responsible for maintenance of the contract research organizations (CRO) preclinical services under the GLP regulation and animal facility under IACUC/AAALAC guidelines in Level Biotech. I received the Bachelor of Pharmacy at Taipei Medical University and obtained the Master and Ph.D. degrees from Institute of Pharmacology, National Yang-Ming University. I also have a pharmacist license in Taiwan. My master thesis studied the vasorelaxing mechanisms of anti-hypertensive candidate drug and Ph.D. dissertation was establishment the systems biology platforms (transcriptomics, proteomics, and bioinformatics) to study the LPS-induced inflammation responses. I completed postdoctoral training at Institute of Biological Chemistry in Academia Sinica and as Adjunct Assistant Professor of Biological Chemistry Course at Department of Life Science in National Taiwan Normal University.
My majors and specialties are the focus on preclinical disease animal models for more than 20 years of experience in pharmacology and toxicology evaluation of drug development. From 2008 to 2016, I was the Researcher/Senior Researcher and Manager of the Pharmacodynamics Development and Animal Laboratory (AAALAC International Accreditation and ISO/IEC 17025/TAF17025 Accreditation) in Industrial Technology Research Institute (ITRI), the world’s top R&D institutes for developing and commercializing advanced technologies in Taiwan. My department had a total of more than 30 research staffs and provide the preclinical study of in vitro/in vivo of pharmacology and toxicology study for NCE (new chemical entity), drug delivery and nanoparticles, herbs drugs, protein drugs, and ADC (antibody-drug conjugates) projects in ITRI. I also developed many oncology models of human cancer cell lines and patient-derived xenograft (PDX) subcutaneous and orthotopic xenograft models and murine allograft tumor models. In addition, I also established many alternative non-animal in vitro methods and developed a novel in vitro method of skin sensitization for toxicology assay of cosmetics and chemicals. From 2016-2018, I am the Director of preclinical Development at APRINOIA Therapeutics Inc. and responsible to develop and supervise the CRO companies and in-house in vivo study of neurodegeneration disease (Alzheimer’s disease, Parkinson disease, glaucoma and brain traumatic injury) animal models for the pipeline candidate drugs (PET tracer, NCE, and monoclonal antibody) efficacy evaluation.
In Level Biotechnology Inc., I am responsible to maintain the contract research organizations (CRO) preclinical services under the TFDA/OECD/USFDA GLP regulation and animal facility under IACUC/AAALAC guidelines for New entity chemical (NEC), biopharmaceutics, medical device, and other related products.
Honors:
The 13th National Innovation Award/國家新創獎 (2016): Precision Medicine: Novel Conjugation Linker Antibodies-Drug Conjugation Drug
The 10th National Innovation Award/國家新創獎 (2013): New Polymer Nano-micelle Technology for Anticancer Drug.
研究兴趣
论文共 42 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ting-Ting Yeh, Ming-Yi Ho,Wei-Ya Chen, Ya-Chen Hsu,Wei-Chi Ku,Hsiang-Wen Tseng,Shih-Ta Chen,Sung-Fang Chen
Zong-Keng Kuo,Po-Liang Lai, Elsie Khai-Woon Toh, Cheng-Hsi Weng,Hsiang-Wen Tseng,Pei-Zen Chang,Chih-Chen Chen,Chao-Min Cheng
SCIENTIFIC REPORTSno. 1 (2016): 32884-32884
Zong-Keng Kuo,Mei-Wei Lin, I-Huang Lu,Hsin-Jan Yao,Hsin-Chieh Wu,Chun-Chung Wang,Shyh-Horng Lin,Si-Yuan Wu, Tien-Soung Tong,Yi-Cheng Cheng,Jui-Hung Yen,Ching-Huai Ko,
Ihorng Pan,Hsinjan Yao,Meiwei Lin, L U Ihuang, W U Hsinchieh,Hsiangwen Tseng, K O Chinghuai,Chunchung Wang,Zongkeng Kuo,Shyhhorng Lin,Yicheng Cheng, Tiensoung Tong
mag(2016)
引用22浏览0引用
22
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn